Core Alternative Capital’s Takeda Pharmaceutical TAK Stock Holding History

Core Alternative Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-138	Closed	-$2K	–	480
2021 Q4	$2K	Buy	+138	New	+$1.94K	﹤0.01%	334

Other funds holding TAK

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Core Alternative Capital's TAK Position: Q1 2022 in Review

Core Alternative Capital sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 138 shares — an estimated $2K sold.

Core Alternative Capital first reported a position in TAK in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 288 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

Core Alternative Capital reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
Core Alternative Capital sold 138 Takeda Pharmaceutical shares in Q1 2022, an estimated $2K.
Core Alternative Capital first reported a position in Takeda Pharmaceutical in Q4 2021 and held it in 1 quarter.
Core Alternative Capital's Takeda Pharmaceutical position peaked at $2K in Q4 2021.
288 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on Core Alternative Capital's 13F filing for Q1 2022, filed 10 May 2022.